Peer-reviewedCC BY-NC-ND 4.0eClinicalMedicine
Pembrolizumab plus gemcitabine and cisplatin for advanced biliary tract cancer: longer-term follow-up from the randomised, double-blind, placebo-controlled, phase 3 KEYNOTE-966 trial
Related
- Cadonilimab plus gemcitabine and cisplatin as first-line treatment for unresectable locally advanced or metastatic biliary tract malignancies: the phase II bicureX clinical trial
- Initial Clinical Experience With Gemcitabine, Cisplatin, and Nivolumab for Advanced Urothelial Carcinoma: A Four-case Series
- Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial
- Combined Hepatocellular-cholangiocarcinoma Patient Treated with Durvalumab Plus Gemcitabine and Cisplatin
- Radiosensitising strategies in locally advanced head and neck cancer: a systematic review and network meta-analysis of randomised controlled trials (RADIANCE-NMA)
BibTeX
@article{ueno2026pembrolizumab,
title = {{Pembrolizumab plus gemcitabine and cisplatin for advanced biliary tract cancer: longer-term follow-up from the randomised, double-blind, placebo-controlled, phase 3 KEYNOTE-966 trial}},
author = {Makoto Ueno and Changhoon Yoo and Zhenggang Ren and Junji Furuse and Robin Kate Kelley and Stephen Lam Chan and Julien Edeline and Heinz-Josef Klümpen and Thomas Yau and Chris Verslype and Masato Ozaka and Mohamed Bouattour and Joon Oh Park and Arndt Vogel and Juan W. Valle and Liis Starkopf and Usha Malhotra and Abby B. Siegel and Shukui Qin and Richard S. Finn and Guillermo Mendez and Ruben Segovia and Marcela Carballido and Soledad Iseas and Julieta Grasselli and Diego Kaen and Margaret Lee and Warren Joubert and Aflah Roohullah and Begbie Stephen and Keri-Lee Geneser and Sumitra Anand and Ivan Borbath and Joelle Collignon and Karen Geboes and Anne Demols and Chris Verslype and Isabelle Sinapi and Rui Weschenfelder and Marcos Camandaroba and Gustavo Alves and Fabio Franke and Ana Beatriz Kinupe Abrahao and Ana Paula Victorino and Camila Moniz and Ricardo Saraiva de Carvalho and Jamil Asselah and Francine Aubin and Elaine McWhirter and Ghazaleh Kazemi and Jacob Easaw and Vincent Tam and Bruno Nervi and Plinio Fernandez and Patricio Yanez Weber and Rodrigo Uribe and Olga Barajas and Pamela Salman and Claudio Painemeal and Luisa Morales},
journal = {eClinicalMedicine},
year = {2026},
month = oct,
doi = {10.1016/j.eclinm.2026.104213},
url = {https://linkinghub.elsevier.com/retrieve/pii/S2589537026004669},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - Pembrolizumab plus gemcitabine and cisplatin for advanced biliary tract cancer: longer-term follow-up from the randomised, double-blind, placebo-controlled, phase 3 KEYNOTE-966 trial
AU - Makoto Ueno
AU - Changhoon Yoo
AU - Zhenggang Ren
AU - Junji Furuse
AU - Robin Kate Kelley
AU - Stephen Lam Chan
AU - Julien Edeline
AU - Heinz-Josef Klümpen
AU - Thomas Yau
AU - Chris Verslype
AU - Masato Ozaka
AU - Mohamed Bouattour
AU - Joon Oh Park
AU - Arndt Vogel
AU - Juan W. Valle
AU - Liis Starkopf
AU - Usha Malhotra
AU - Abby B. Siegel
AU - Shukui Qin
AU - Richard S. Finn
AU - Guillermo Mendez
AU - Ruben Segovia
AU - Marcela Carballido
AU - Soledad Iseas
AU - Julieta Grasselli
AU - Diego Kaen
AU - Margaret Lee
AU - Warren Joubert
AU - Aflah Roohullah
AU - Begbie Stephen
AU - Keri-Lee Geneser
AU - Sumitra Anand
AU - Ivan Borbath
AU - Joelle Collignon
AU - Karen Geboes
AU - Anne Demols
AU - Chris Verslype
AU - Isabelle Sinapi
AU - Rui Weschenfelder
AU - Marcos Camandaroba
AU - Gustavo Alves
AU - Fabio Franke
AU - Ana Beatriz Kinupe Abrahao
AU - Ana Paula Victorino
AU - Camila Moniz
AU - Ricardo Saraiva de Carvalho
AU - Jamil Asselah
AU - Francine Aubin
AU - Elaine McWhirter
AU - Ghazaleh Kazemi
AU - Jacob Easaw
AU - Vincent Tam
AU - Bruno Nervi
AU - Plinio Fernandez
AU - Patricio Yanez Weber
AU - Rodrigo Uribe
AU - Olga Barajas
AU - Pamela Salman
AU - Claudio Painemeal
AU - Luisa Morales
PY - 2026
DA - 2026/10/01
JO - eClinicalMedicine
DO - 10.1016/j.eclinm.2026.104213
UR - https://linkinghub.elsevier.com/retrieve/pii/S2589537026004669
SN - 2589-5370
ER -